Progen Industries Ltd. 16 Benson Street Toowong, QLD 4066 Phone: 61 7 3842 3333 Fax: 61 7 3720 9624 Web Site: http://www.progen.com.au Toll free - Australia: 1 800 500 485 International -- USA: 1 888 891 6274 Participant code: 763078 Media and Investor Relations: Rebecca Wilson Buchan Consulting rwilson@bcg.com.au Ph: +61 2 9237 2800 / 0417 382 391 Progen Information: Sarah Meibusch Director, Business Development Progen Industries Limited Sarah.Meibusch@progen.com.au Ph: +61 7 3842 3333 ============================================================= Progen Industries Limited, a biotechnology company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and other diseases. The company's products include PI-88, a multifunctional and multitargeted cancer therapeutic, which is in phase II clinical trial, inhibiting both angiogenesis and tumor promoting factors, such as vascular endothelial growth factor, fibroblast growth factor 1, fibroblast growth factor 2, and heparanase. Its second oncology product, PI-166 is in phase Ib clinical trial in patients with inoperable primary liver cancer. Progen Industries also develops small molecule drug candidates that modulate the interaction between carbohydrates and disease-related protein targets as potential therapeutics for cancer. The company also provides contract manufacturing and bioprocess technology development services. It has a strategic alliance with Medigen Biotechnology Corporation for PI-88 clinical trials. Progen Industries was founded by Stephen Chang in 1989 as Almagest Pty., Ltd. and changed its name to Progen Industries Pty., Ltd. in 1990. Further, it changed its name to Progen Industries Limited in 1991. The company is based in Darra, Australia. ==============================================================